If there’s one megatrend that looks set to dominate the next couple of decades, it is artificial intelligence (AI).

From data centres and semiconductors to cybersecurity and advanced robotics, AI is reshaping the global economy.

The good news is that there are a number of exchange traded funds (ETFs) out there that give investors exposure to these markets.

Let’s see why three listed below could be top options for investors looking to make investments that they don’t have to touch for the next 10 to 20 years.

Betashares Asia Technology Tigers ETF (ASX: ASIA)

Asia is fast becoming the production line for the AI boom. Betashares notes that a huge share of global AI infrastructure depends on Asian technology leaders, especially within the semiconductor supply chain.

Taiwan Semiconductor Manufacturing Co. (NYSE: TSM) and South Korean memory giants SK Hynix (KRX: 000660) and Samsung Electronics supply critical components such as accelerator chips and high-bandwidth memory, with TSMC alone recently reporting a 30% surge in quarterly sales driven by AI demand.

The Betashares Asia Technology Tigers ETF offers simple exposure to these companies. Its portfolio is also packed with industry heavyweights, including Tencent Holdings (SEHK: 700), Alibaba Group (NYSE: BABA), PDD Holdings (NASDAQ: PDD), and Baidu (NASDAQ: BIDU), which all have their own exposure to AI.

For long-term investors, this ASX ETFs provides a powerful way to tap into the AI boom.

Betashares Global Cybersecurity ETF (ASX: HACK)

As AI technology grows more capable, so too do the threats. This means that cybersecurity is now one of the most resilient and fastest-growing industries within the digital economy.

Betashares notes that spending on security software is “least likely to be cut” even in downturns, and global cybersecurity spending is expected to hit US$377 billion by 2028.

The Betashares Global Cybersecurity ETF gives investors exposure to global leaders such as CrowdStrike Holdings (NASDAQ: CRWD), Palo Alto Networks (NASDAQ: PANW), and Fortinet (NASDAQ: FTNT). These are companies developing AI-powered security tools capable of detecting and neutralising threats at machine speed.

Over a 20-year horizon, cybersecurity could be about as close as it gets to a non-negotiable global necessity.

Betashares Global Robotics and Artificial Intelligence ETF (ASX: RBTZ)

The Betashares Global Robotics and Artificial Intelligence ETF is another ASX ETF to consider for the long term.

It provides exposure to companies leading the AI and robotics shift, including ABB Ltd (SWX: ABBN), Nvidia Corp (NASDAQ: NVDA), and FANUC Corp (TYO: 6954). These businesses supply the automation tools, industrial robots, sensors, and AI-enhanced systems that will increasingly power factories, warehouses, transport networks, and healthcare facilities.

Betashares recently recommended the fund to investors.

The post 3 exciting ASX ETFs to buy and hold for 20 years appeared first on The Motley Fool Australia.

More reading

• The ASX ETFs I’d buy for my kids or grandkids
• 2 ASX stocks I’m very bullish about for the next decade
• Want to invest in AI? These ASX ETFs give you instant exposure
• Where to invest $10,000 in ASX ETFs this December
• The 10-year wealth plan: how to turn small savings into life-changing results

Motley Fool contributor James Mickleboro has positions in Betashares Capital – Asia Technology Tigers Etf. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Abb, BetaShares Global Cybersecurity ETF, CrowdStrike, Fortinet, Nvidia, Taiwan Semiconductor Manufacturing, and Tencent. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Alibaba Group, Fanuc, and Palo Alto Networks. The Motley Fool Australia has recommended CrowdStrike and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you have a spare $10,000 and aren’t sure where to invest it, here are the ASX shares I’m currently watching.

CSL (ASX: CSL)

After suffering a brutal sell-off in late August and again in late October when the company downgraded its FY26 revenue and profit growth guidance, I think the worst is now over for CSL shares.

Since the latest price plunge, CSL shares have climbed just over 6.5%. The share price is 0.08% higher at $182.45 at the time of writing this morning, and I’m optimistic that this signals that investor sentiment is now turning more positive. It could mean we’re going to see green shoots of recovery for the ASX biotech company’s shares.

CSL shares were the fifth most-traded by CommSec clients last week, over half of which was buying activity. If investor interest begins to pick up, it could mean that the share price does too. 

Data shows the majority of analysts have a buy rating on the shares with a target price as high as $278.05. That implies a potential 52.44% upside at the time of writing.

Electro Optic Systems Holdings Ltd (ASX: EOS)

For exposure to the booming defence market, I’d look no further than EOS shares. The Australian company, which develops and produces advanced electro-optic technologies and is focused on the defence space, is well placed to benefit from demand arising from ongoing geopolitical uncertainty. 

At the time of writing, the shares are up 2.24% at $4.56 each. Analysts are very bullish about the shares too, and all hold a strong buy rating. The maximum target price is $11.18, implying that the stock could surge by a substantial 143% over the next 12 months, at the time of writing.

WiseTech Global Ltd (ASX: WTC)

In the tech space, I have my money on WiseTech shares in 2026. Despite a market sell-off of tech shares in late November, the company has previously demonstrated resilience and growth through economic cycles. It’s also well-positioned to benefit from increased interest trends like automation and cloud computing.

I think this current low price presents a fantastic buying opportunity for investors. 

At the time of writing, the shares are 4.35% higher at $75.74 a piece. The data shows that analysts are also bullish on the ASX tech company’s shares. Out of 18 analysts, 14 have a buy or strong buy rating, with a maximum target price of $177.31. That implies the shares could storm 134.19% higher.

Woolworths Group Ltd (ASX: WOW)

When it comes to building passive income, Woolworths is high on my list. The company offers reliable dividend payments supported by defensive earnings, strong cash flow, and a dominant position in the Australian retail market.

The shares are trading 0.37% lower at the time of writing on Thursday morning at $29.31. Over the year, the shares are still down 2.23% thanks to a sharp sell-off after the company posted a disappointing FY25 result. Although the supermarket giant’s first-quarter sales update in late October provided some relief to investors. 

The supermarket giant is well-placed to recover over FY26, and I think there is a good opportunity to buy the shares ahead of its resurgence. Data shows that analyst sentiment is also turning. Out of 17 investors, 7 have a buy or strong buy rating on the shares with a maximum price target of $33. This implies a potential 12.51% upside for investors over the next 12 months, at the time of writing.

Bell Potter, which is one of the brokers with a buy rating on the stock, expects the company to pay fully franked dividends of 91 cents per share in FY26 and then 100 cents per share in FY27. 

The post 4 ASX shares I’d buy today with $10,000 appeared first on The Motley Fool Australia.

More reading

• 2 cheap Australian shares under $50 to buy this December
• These ASX innovators could be the market’s next big winners
• Here are the top 10 ASX 200 shares today
• 3 high-quality ASX 200 shares now trading at multi-year discounts
• Forget Zip shares: Here’s why Xero and WiseTech are better tech bets for 2026

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Electro Optic Systems, and WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global and Woolworths Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

National Australia Bank Ltd (ASX: NAB) shares are edging lower today.

Shares in the S&P/ASX 200 Index (ASX: XJO) bank stock closed yesterday trading for $40.42. In morning trade on Thursday, shares are changing hands for $40.26 apiece, down 0.2%.

For some context, the ASX 200 is up 0.2% at this same time.

That’s today’s price action for you.

Now, here’s how NAB is working to strengthen its business lending arm.

NAB shares aim to hold their business lending edge

Amid fierce ongoing competition in Australia’s mortgage lending, Commonwealth Bank of Australia (ASX: CBA) and Westpac Banking Corp (ASX: WBC) have both been working to boost their business lending, which tends to offer higher profit margins.

If they’re successful, that could put NAB shares under pressure as the bank has traditionally been the leader in business lending.

In response, NAB announced this morning that it is targeting growth in the medium and large business segments. The bank said it is expanding a specialist team of bankers to originate deals and “support a seamless customer experience”.

The new group will bring together expert business bankers from across NAB’s business & private banking and corporate & institutional banking teams.

The team will focus on new opportunities in the growing medium and large business segments for the bank. A support team will also help to fast-track customer approvals, simplify onboarding, and bring whole-of-bank solutions to NAB’s customers.

The overall idea it to reduce the complexity for customers and bankers, which NAB said can often accompany larger transactions.

What did management say?

Commenting on the new specialist team that’s intended to support NAB shares over time, corporate & institutional banking executive Cathryn Carver said, “There is no area more important to us and our customers than business banking, our heartland.”

Carter continued:

While competition has intensified in recent years, we’ve made it very clear that we’re focussed on extending our market leadership.

We’re taking the best business banking capability from across NAB and creating a team that will be the cornerstone of what being the most customer-centric company in Australia and New Zealand looks like.

NAB business & private banking executive Andrew Auerbach said, “One in three agribusinesses and one in four SME businesses bank with NAB.”

Auerbach added:

With this expansion, we believe we can help meet the ambitions of even more medium and large businesses in Australia. By combining specialist sector expertise, deep local relationships and the full breadth of NAB’s balance sheet, we’re delivering faster, more coordinated support to our customers.

With today’s intraday moves factored in, NAB shares are up 8.2% in 2025.

The post Buying NAB shares? Here’s how the bank aims to cement its market leading business appeared first on The Motley Fool Australia.

More reading

• Forget Westpac shares and buy these ASX dividend stocks
• Westpac versus CBA shares: Which bank is a better buy for 2026?
• Analysts rate CBA and these popular ASX shares as sells
• 5 most-traded Australian shares last week
• ANZ shares are lagging the other big banks: Here’s why

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Argenica Therapeutics Ltd (ASX: AGN) are trading more than 20% higher after the company released positive clinical trial results.

Argenica, in its own words, is “a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke”.

No adverse interactions a positive

The company said in a statement to the ASX on Thursday that it was pleased to report the results of a study of its lead drug candidate ARG-007 and its interaction with clot dissolving agent tenecteplase (TNK).

As the company said:

The purpose of this study was to determine whether ARG-007 interferes with the clot dissolving activity of TNK, a genetically modified version of alteplase and a recombinant tissue plasminogen activator, recently approved by the FDA (Food & Drug Administration) for the treatment of acute ischemic stroke.

The company said blood clots from four donors were assessed as part of the trial, which found that ARG-007 did not inhibit the clot dissolving effect of TNK.

The company said further:

This finding is particularly important because demonstrating a lack of inhibition of the activity of clot dissolving drugs is a key FDA requirement when developing a neuroprotective therapy intended to be used alongside standard-of-care thrombolytics like TNK. Confirming that ARG 007 does not interfere with TNK’s mechanism of action significantly de-risks the program, supports the overall safety profile of the drug, and represents a critical step toward resolving the FDA’s questions and advancing the investigational new drug application.

Building on previous results

Argenica said this new study complemented a previous study which also showed no adverse interactions with another drug called alteplase.

The company said it would now move ahead with necessary submissions to the FDA.

With the TNK drug–drug interaction study now successfully completed, Argenica will incorporate these results into its formal response to the US FDA, addressing one of the key requirements outlined in the FDA’s clinical hold letter1. The two remaining FDA-requested assays have already commenced, and the Company anticipates data from these studies to be available in Q1 CY26. To further strengthen the IND package, Argenica is generating additional data on the maximum tolerated dose of ARG-007 in rats to help inform the clinical safety margin for dosing in humans, as well as collating safety data from the recently completed Phase 2 clinical trial to ensure the FDA has all the relevant data required to lift the clinical hold.

Argenica shares were trading 20.4% higher at 26.5 cents on the news on Thursday. The company was valued at $28.3 million at the close of trade on Wednesday.  

The post Which junior biotech’s shares are flying on positive trial news? appeared first on The Motley Fool Australia.

More reading

• Pro Medicus responds to data breach speculation: no client or patient data accessed
• Regis Healthcare sells two QLD homes for $25 million gain
• Bendigo and Adelaide Bank unveils RACQ Bank acquisition in investor update
• 5 things to watch on the ASX 200 on Thursday
• ASX dividend shares: How to snowball your passive income

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Fletcher Building Ltd (ASX: FBU) share price is 1.8% lower at the time of writing on Thursday morning, at $3 a piece. There have been many peaks and troughs over the past 12 months, but the share price is currently sitting 15.19% higher than this time last year. 

The dual-listed New Zealand-based building and materials company’s shares are also 0.29% lower on the NZE this morning, at NZ$3.45 per share. 

The company reported ongoing declines in trading volumes for the first quarter of FY26 and expects challenging conditions to continue for the remainder of the period. While the results were weak, Fletcher Building said it has launched a new cost-out and efficiency programme, targeting around NZ$100 million in annualised savings.

But the team at Macquarie Group Ltd (ASX: MQG) has an underperform rating on this ASX 200 stock. And they expect there could be a significant share price fall in the near future. 

Heavy downside ahead for Fletcher Building

In a note to investors this morning, Macquarie confirmed its underperform rating on Fletcher Building shares. However, the broker raised the company’s target price to NZ$1.73, up from NZ$1.59 previously.

Despite the increase, using the NZ$3.45 share price at the time of writing, that still implies potential for a huge 49.9% downside over the next 12 months.

“We raise our TP by 9% to $1.73, from $1.59, on lower RfR rollforward (4.3% or -20bps)… Maintain Underperform given predominantly negative catalysts. Prior FBU research,” the broker said in its note.

Strong headwinds in the pipeline for the ASX 200 stock

Macquarie analysts pointed out in the note that NZ residential consents have strengthened over the past three months, up 11% compared to the prior period. 

“This runs against our view that house consenting levels are running ~30% above sustainable levels,” the broker said.

Macquarie also said that moves by local governments to shift local road and water infrastructure costs back to residential land developers (away from rate payers and taxpayer-funded transfers) may be pulling forward consenting activity. 

“In Auckland, development contributions lifted 88% from $24k to $45/k per consented house on avge in greenfield areas. This additional impost falls on resource consents (and related BCs) lodged after 1-Jul-2025. We note that according to the gov’t (INZ), Auckland developers have historically paid two-thirds of new infrastructure via DCs.”

The broker doesn’t think this pull-forward of activity will be confined to Auckland either, given the new 2026 legislation will be NZ-wide from 2027.

“Moreover, legislation to cap council rate increases and council shifts to reflect the government’s National Policy Statement on increased intensification (e.g., ACC’s PC120) reinforce the objective of moving more infra cost to developers, while at the same time encouraging earlier rather than later development,” the broker said.

“Some may point to conventional monetary policy impact on demand, but with increasing unsold inventory levels (11-yr high noted by FBU) and low population growth, we do not share this view.” 

The post This ASX 200 stock could plummet 50% next year appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Warning! Analysts think it’s time to sell these 3 ASX 200 shares
• 5 ASX 200 stocks I’m avoiding this week
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Pro Medicus Ltd (ASX: PME) share price is in focus after addressing speculation of a potential data breach, confirming no client or patient data was accessed and no financial loss occurred.

What did Pro Medicus report?

• Investigated unauthorised access of a single company email inbox in July 2025
• No client systems or patient data were accessed
• No Pro Medicus products, systems, or databases were affected
• No operational impact or financial loss resulted from the incident
• Potential exposure of personal data for approximately 100 current and former employees
• All impacted individuals have been notified

What else do investors need to know?

The company confirmed the cybersecurity incident was isolated to a single mailbox and was quickly contained with the help of external experts. There is no evidence that any commercially sensitive or material information was accessed during the breach.

Pro Medicus has informed all applicable government authorities as required by law, and all directly affected employees were promptly notified about the possible personal data exposure.

What’s next for Pro Medicus?

Pro Medicus states that its systems and client information remain secure. The company continues to review its cybersecurity practices and is committed to protecting data in line with industry best practice.

There is no expectation of financial or operational impact, with Pro Medicus focusing on its ongoing delivery of medical imaging software solutions and services worldwide.

Pro Medicus share price snapshot

Over the past 12 months, Pro Medicus shares have declined 3%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 2% over the same period.

View Original Announcement

The post Pro Medicus responds to data breach speculation: no client or patient data accessed appeared first on The Motley Fool Australia.

More reading

• Regis Healthcare sells two QLD homes for $25 million gain
• Bendigo and Adelaide Bank unveils RACQ Bank acquisition in investor update
• 5 things to watch on the ASX 200 on Thursday
• ASX dividend shares: How to snowball your passive income
• These ASX innovators could be the market’s next big winners

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The DGR Global Ltd (ASX: DGR) share price has more than doubled over the past week, turning the stock into a fabled “10-bagger” over the past year.

The company’s shares have traded as low as 0.3 cents in the past 12 months, but hit a high of 4.6 cents earlier in the week, on news that one of its portfolio investments had received a takeover proposal from a Chinese company.

Chinese bid rejected

DGR told the ASX in a statement released earlier this week that the London Stock Exchange-listed SolGold Plc (LSE: SOLG) had last week rejected a conditional and non-binding takeover bid from Jiangxi Copper (Hong Kong) Investment Company Ltd (JCC).

The bid was priced at 26 pence per SolGold share, with the SolGold share price shooting beyond that level to be trading at 30 pence currently.

This is good news for DGR, as it is a major shareholder in SolGold along with some heavy hitters in the resources sector.

As the company said:

DGR is the fourth largest shareholder of SolGold holding a beneficial interest in 204 million shares or 6.80% of SolGold behind JCC with 366 million shares (12.18%), BHP Billiton with approximately 311 million shares (10.36%) and Newcrest International with 309 million (10.3%). DGR’s holding in SolGold is DGR’s largest asset, forming 95% of the marked to-market asset base of DGR.

DGR’s shareholding in SolGold, calculated at the 30 pence share price currently, is worth about $123 million, which is about triple the value of DGR shares listed on the ASX, with the company’s market capitalisation coming in at just $39.7 million.

Major project shaping up well

SolGold, which was founded by DGR and listed on the London Stock Exchange in 2006, owns the Cascabel project in northern Ecuador, “on the prolific Andean Copper Belt, the northern Chilean sector of which hosts an estimated 25% of the worlds copper resources and production”.

As DGR said this week:

Based on consensus metal pricing at 16 February 2024, of just US$1,750/oz gold and US$3.85 /lb copper, an independent prefeasibility study into the staged development of the core of (the) Alpala deposit at an 8% discount rate, an initial 12 million tonne per annum underground production rate and a pre-production capex of US$1.55 Billion was completed and demonstrated an after tax net present value of US$3.2Billion and an after-tax internal rate of return of 24% on just 18% of the resource being mined over just the first 28 years. At the then current consensus pricing, the project showed the modelled delivery of over US$7.1 Billion in free cashflows over the first 10 years of production.   

DGR said the project had not been reassessed at more recent long-run gold and copper prices, or with the addition of a new open-pit project nearby.

DGR chair Peter Wright said the takeover approach by JCC indicated the value in SolGold’s flagship project.

DGR shares were changing hands for 4.4 cents on Thursday morning, up from 1.8 cents before the JCC approach was revealed.

The post Why has a UK takeover bid lit a fire under this copper prospector’s share price? appeared first on The Motley Fool Australia.

More reading

• Rio Tinto or BHP shares? Expert says which stock to buy as copper price smashes record
• 3 ASX dividend shares to buy for a passive income stream
• Rio Tinto versus BHP shares: One I’d buy and one I’d sell
• What happened with BHP, Rio Tinto and Fortescue shares in November?
• Is the BHP share price a buy for passive income?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

With December now underway, investors looking for value on the ASX don’t need to search far.

A number of high-quality Australian shares have pulled back sharply in 2025’s market volatility, creating rare opportunities to buy strong businesses at much cheaper prices.

If you’re hunting for standout shares under $50, two names in particular look attractively priced heading into the final weeks of the year. They are as follows:

Woolworths Group Ltd (ASX: WOW)

Woolworths has long been considered one of the safest, most dependable companies on the ASX. Its dominant supermarket network, defensive earnings, and consistent cash generation have made it a staple in countless retirement and dividend portfolios.

Yet, despite its resilience, Woolworths shares have slid materially from their highs and now trade at $29.42.

Much of the weakness has stemmed from short-term concerns about market share pressure and value-conscious shoppers shifting toward discounted products during the cost-of-living squeeze.

But none of this changes Woolworths’ long-term appeal. The company continues to hold a dominant market position, enjoys deep customer loyalty, and is steadily expanding its digital, online, and data-driven capabilities. Its non-cyclical business model means earnings remain remarkably stable through economic cycles, which is something few businesses can claim right now.

For investors seeking a high-quality, under-$50 stock with a strong history of consistent returns, Woolworths could be just the ticket.

Ord Minnett currently rates it as a buy with a $33.00 price target.

GQG Partners Inc (ASX: GQG)

Another Australian share that looks cheap is GQG Partners.

It is a fund manager specialising in global equities with a focus on high-quality companies.

However, its decision to sit out the AI trade on bubble fears means that its funds have been underperforming this year. This has led to a decline in funds under management and an even greater decline in its share price.

However, its shares are now looking seriously oversold. So much so, analysts think they offer major upside and 10%+ dividend yields in the near term. This could make them a top option for value investors in the current environment.

Macquarie remains bullish on the company and has an outperform rating and $2.50 price target on its shares. This suggests that upside of 40% is possible from its last close price of $1.79.

Overall, at these levels, GQG looks like a quality business trading well below its fair value, offering both income and capital growth potential.

The post 2 cheap Australian shares under $50 to buy this December appeared first on The Motley Fool Australia.

More reading

• 3 high-yield ASX dividend stocks that are screaming buys right now
• Brokers name 3 ASX dividend shares to buy in December
• 3 ASX dividend stocks I’d trust with my retirement savings
• Own Woolworths shares? Here are the dividend dates for 2026
• Forget term deposits and buy these ASX dividend shares

Motley Fool contributor James Mickleboro has positions in Gqg Partners and Woolworths Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Woolworths Group. The Motley Fool Australia has recommended Gqg Partners. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.